AOD-9604 Promotes Fat Loss Without Affecting Blood Glucose in Phase II Obesity Trial

AOD-9604 is compelling because it isolates the fat-burning effects of growth hormone without the metabolic side effects. Full GH raises blood sugar and can promote insulin resistance over time—exactly what you're trying to avoid in metabolic optimization. AOD-9604 is a modified fragment of GH's C-terminus that retains lipolytic activity but doesn't bind GH receptors, meaning you get the fat mobilization without glucose dysregulation. This is crucial for anyone concerned about insulin sensitivity or pre-diabetes. The fact that it specifically targeted abdominal fat—the metabolically harmful visceral depot—makes it relevant for body composition goals that go beyond aesthetics into actual metabolic health improvement.

AOD-9604 (Advanced Obesity Drug) was developed by Metabolic Pharmaceuticals specifically to separate growth hormone's fat-reducing effects from its other metabolic actions. The peptide is the 176-191 amino acid fragment of human growth hormone, modified with a di-sulfide bridge for stability. This 2007 Phase II trial was part of its development as an anti-obesity drug, though it ultimately didn't achieve regulatory approval due to mixed efficacy results across different trial populations. The mechanism appears to involve mimicking how GH stimulates beta-3 adrenergic receptors on fat cells, triggering lipolysis without requiring GH receptor activation. While AOD-9604 didn't become a pharmaceutical drug, the research established that selective lipolytic signaling is possible without full GH activity, making it interesting for research into targeted fat metabolism.

The effect of an oral growth hormone secretagogue (MK-677) on body composition in obese males